WBI Investments LLC Has $2.70 Million Stock Holdings in Bristol Myers Squibb Company $BMY

WBI Investments LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 205.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,803 shares of the biopharmaceutical company’s stock after purchasing an additional 40,237 shares during the quarter. Bristol Myers Squibb makes up approximately 0.7% of WBI Investments LLC’s portfolio, making the stock its 22nd largest holding. WBI Investments LLC’s holdings in Bristol Myers Squibb were worth $2,697,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC boosted its stake in Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the period. United Bank grew its holdings in Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares during the last quarter. Citizens Financial Group Inc. RI increased its position in Bristol Myers Squibb by 25.1% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 44,213 shares of the biopharmaceutical company’s stock worth $2,047,000 after buying an additional 8,876 shares during the period. Finally, Western Wealth Management LLC increased its position in Bristol Myers Squibb by 14.8% in the 2nd quarter. Western Wealth Management LLC now owns 22,673 shares of the biopharmaceutical company’s stock worth $1,050,000 after buying an additional 2,923 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $59.71 on Wednesday. The firm has a market capitalization of $121.59 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The business has a fifty day simple moving average of $58.47 and a 200 day simple moving average of $51.64. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research reports. Barclays initiated coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their target price for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Leerink Partners raised their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective on the stock. Finally, Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.41.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.